Dynavax Technologies said on Thursday its experimental shingles vaccine generated a similar immune response as GSK's ...

A study published this week in the peer-reviewed journal Scientific Reports examined the long-term impacts of having shingles ...

Results from the first part of a Phase I/II trial (NCT06569823) showed that Z-1018 generated immune responses comparable to ...

Dynavax Technologies Corporation (NASDAQ:DVAX) surged 8% Thursday following the announcement of encouraging topline data from ...

The Emeryville, California-based biotech has just released topline results from a phase 1/2 head-to-head study comparing its ...

Shares of Dynavax rose after the company released positive results from a trial of its shingles vaccine tested against current Shingles vaccine Shingrix. The stock was up 6.7% to $11.12 but is still ...

FOX 32's Elizabeth Matthews shares her painful and vision-threatening battle with shingles on her face and eye to raise awareness that the illness can strike younger, healthy adults.

The recombinant herpes zoster vaccine (Shingrix) was not only associated with a reduced risk of herpes zoster ophthalmicus ...

Shingles, also called herpes zoster, is a condition caused by the same virus as chickenpox. About 350,000 Americans get chickenpox each year, which causes an itchy rash that lasts about a week.